Calpain inhibitors: a survey of compounds reported in the patent and scientific literature

Bibliography

• Saez ME, Ramirez-Lorca R, Moron FJ, The therapeutic potential of the calpain family: new aspects. Drug Discov Today 2006;11:917-23
   PubMed Web of Science ®Google Scholar
• Croall DE, Ersfeld K. The calpains: modular designs and functional diversity. Genome Biol 2007;8:218
   PubMed Web of Science ®Google Scholar
• Sorimachi H, Hata S, Ono Y. Expanding members and roles of the calpain superfamily and their genetically modified animals. Exp Anim 2010;59(5):549-66
   PubMed Web of Science ®Google Scholar
• Kuchay SM, Chishti AH. Calpain-mediated regulation of platelet signaling pathways. Curr Opin Hematol 2007;14:249-54
   PubMed Web of Science ®Google Scholar
• Vaisid T, Kosower NS, Katzav A, Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. Neurochem Int 2007;51(6-7):391-7
   PubMed Web of Science ®Google Scholar
• Camins A, Verdaguer E, Folch J, Pallas M. Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 2006;12:135-48
   PubMedGoogle Scholar
• Bevers MB, Neumar RW. Mechanistic role of calpains in postischemic neurodegeneration. J Cereb Blood Flow Metab 2008;28:655-73
   PubMed Web of Science ®Google Scholar
• Raynaud F, Marcilhac A. Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease. FEBS J 2006;273:3437-43
   PubMed Web of Science ®Google Scholar
• Saatman KE, Creed J, Raghupathi R. Calpain as a therapeutic target in traumatic brain injury. Neurotherapeutics 2010;7(1):31-42
   PubMed Web of Science ®Google Scholar
• Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 2008;38:78-100
   PubMed Web of Science ®Google Scholar
• Randriamboavonjy V, Fleming I. The role of calpain in diabetes-associated platelet hyperactivation. Adv Pharmacol 2010;59:235-57
   PubMedGoogle Scholar
• Harris F, Biswas S, Singh J, Calpains and their multiple roles in diabetes mellitus. Ann NY Acad Sci 2006;1084:452-80
   PubMed Web of Science ®Google Scholar
• Azuma M, Shearer TR. The role of calcium-activated protease calpain in experimental retinal pathology. Surv Ophthalmol 2008;53:150-63
   PubMed Web of Science ®Google Scholar
• Paquet-Durand F, Johnson L, Ekstrom P. Calpain activity in retinal degeneration. J Neurosci Res 2007;85:693-702
   PubMed Web of Science ®Google Scholar
• Biswas S, Harris F, Dennison S, Calpains: enzymes of vision? Med Sci Monit 2005;11:RA301-10
   PubMed Web of Science ®Google Scholar
• Zadran S, Bi X, Baudry M. Regulation of calpain-2 in neurons: implications for synaptic plasticity. Mol Neurobiol 2010;42:143-50
   PubMed Web of Science ®Google Scholar
• Tidball JG, Spencer MJ. Calpains and muscular dystrophies. Int J Biochem Cell Biol 2000;32:1-5
   PubMed Web of Science ®Google Scholar
• Zatz M, Starling A. Calpains and disease. Engl J Med 2005;352:2413-23
   PubMed Web of Science ®Google Scholar
• Bertipaglia I, Carafoli E. Calpains and human disease. Subcell Biochem 2007;45:29-53
   Google Scholar
• Leloup L, Wells A. Calpains as potential anti-cancer targets. Expert Opin Ther Targets 2011;15:309-23
   PubMed Web of Science ®Google Scholar
• Libertini SJ, Tepper CG, Rodriguez V, Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007;67:9001-5
   PubMed Web of Science ®Google Scholar
• Mamoune A, Luo J-H, Lauffenburger DA, Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 2003;63:4632-40
   PubMed Web of Science ®Google Scholar
• Parker Hughes Institute. Calpain inhibitors in cancer treatment. WO2001074381; 2001
   Google Scholar
• The Trustees of Columbia University in the City of New York. Uses of calpain inhibitors to inhibit inflammation. WO2009145956; 2009
   Google Scholar
• Passiatore G, Rom S, Eletto D, HIV-1 Tat C-terminus is cleaved by calpain 1: implication for Tat-mediated neurotoxicity. Biochim Biophys Acta 2009;1793(2):378-87
   PubMed Web of Science ®Google Scholar
• Teranishi F, Liu Z-Q, Kunimatsu M, Calpain is involved in the HIV replication from the latently infected OM10.1 cells. Biochem Biophys Res Commun 2003;303:940-46
   PubMed Web of Science ®Google Scholar
• O'Donnell LA, Agrawal A, Jordan-Sciutto KL, Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes 2A and 2B and the calcium-activated protease calpain by a CSF-derived HIV-1 strain. J Neurosci 2006;26:981-90
   PubMed Web of Science ®Google Scholar
• Pietsch M, Chua KC, Abell AD. Calpains: attractive targets for the development of synthetic inhibitors. Curr Top Med Chem 2010;10:270-93
   PubMed Web of Science ®Google Scholar
• DePetrillo PB. Calpains inhibitors–a review of the recent patent literature. IDrugs 2002;5:568-76
   PubMedGoogle Scholar
• Ai J, Liu E, Wang J, Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma 2007;24:960-78
   PubMed Web of Science ®Google Scholar
• Frederick JR, Chen Z, Bevers MB, Neuroprotection with delayed calpain inhibition after transient forebrain ischemia. Crit Care Med 2008;36:S481-5
   Web of Science ®Google Scholar
• Neuhof C, Verena F, Deibele K, Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts. Biol Chem 2004;385:1077-82
   PubMed Web of Science ®Google Scholar
• Lee HY, Morton JD, Robertson LJ. Evaluation of a novel calpain inhibitor as a treatment for cataract. Clin Exp Ophthalmol 2008;36:852-60
   PubMed Web of Science ®Google Scholar
• Logie LJ, Brown AE, Yeaman SJ. Calpain inhibition and insulin action in cultured human muscle cells. Mol Genet Metab 2005;85:54-60
   PubMed Web of Science ®Google Scholar
• Hoang MV, Smith LE, Senger DR. Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. Biochim Biophys Acta 2010. [Epub ahead of print]
   Google Scholar
• Carragher NO. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006;12:615-38
   PubMed Web of Science ®Google Scholar
• Samantaray S, Ray SK, Banik NL. Calpain as a potential therapeutic target in Parkinson's disease. CNS Neurol Disord Drug Targets 2008;7(3):305-12
   PubMed Web of Science ®Google Scholar
• Moldoveanu T, Hosfield CM, Lim D, A Ca2+ switch aligns the active Site of calpain. Cell 2002;108:649-60
   PubMed Web of Science ®Google Scholar
• Neffe AT, Abell AD. Developments in the design and synthesis of calpain inhibitors. Curr Opin Drug Discov Devel 2005;8:684-700
   PubMedGoogle Scholar
• Suzuki K, Hata S, Kawabata Y, Structure, Activation, and Biology of Calpain. Diabetes 2007;53:S12-18
   Google Scholar
• Donkor IO. A survey of calpain inhibitors. Curr Med Chem 2000;7:1171-88
   PubMed Web of Science ®Google Scholar
• Nakajima R, Takao K, Shu-Ming Huang S-M, Comprehensive behavioral phenotyping of calpastatin-knockout mice. Mol Brain 2008:1:7
   PubMed Web of Science ®Google Scholar
• Hanna RA, Campbell RL, Davies PL. Calcium bound structure of calpain and its mechanism of inhibition by calpastatin. Nat Lett 2008;456:409-12
   PubMed Web of Science ®Google Scholar
• Betts R, Weinsheimer S, Blouse GE, Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. J Biol Chem 2003;278:7800-09
   PubMed Web of Science ®Google Scholar
• Gil-Parrado S, Assfalg-Machleidt I, Fiorino F, Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetratin. Biol Chem 2003;384:395-402
   PubMed Web of Science ®Google Scholar
• Fiorino F, Gil-Parrado S, Assfalg-Machleidt I, A new cell-permeable calpain inhibitor. J Pept Sci 2007;13:70-3
   PubMed Web of Science ®Google Scholar
• Wu H-Y, Tomizawa K, Matsushita M, Poly-arginine-fused calpastatin peptide, a living cell membranepermeable and specific inhibitor for calpain. Neurosci Res 2003;47:131-5
   PubMed Web of Science ®Google Scholar
• Pfizer J, Assfalg-Machleidt I, Machleidt W, Inhibition of human μ-calpain by conformationally constrained calpastatin peptides. Biol Chem 2000;389: 83 90
   Google Scholar
• Jiao W, McDonald DQ, Coxon JM, Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. Biochem 2010;49:5533-9
   PubMed Web of Science ®Google Scholar
• The New England Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain. US6015787; 2000
   Google Scholar
• The New England Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain. US6294518; 2001
   Google Scholar
• The New England Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain. US6867186; 2005
   Google Scholar
• Guttmann RP, Day GA III, Wang X, Identification of a novel calpain inhibitor using phage display. Biochem Biophy Res Commun 2005;333:1087-92
   PubMed Web of Science ®Google Scholar
• McCollum AT, Jafarifar F, Lynn BC, Inhibition of calpain-mediated cell death by a novel peptide inhibitor. Exp Neurol 2006;202:506-13
   PubMed Web of Science ®Google Scholar
• Vive's E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-17
   PubMed Web of Science ®Google Scholar
• Pooga M, Hyllbrink M, Zorko M, Cell penetration by transportan. FASEB J 1998;12:67-77
   PubMed Web of Science ®Google Scholar
• Elmquist A, Lindgren M, Bartfai T, VE-cadherin derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 2001;269:237-44
   PubMed Web of Science ®Google Scholar
• Oehlke J, Scheller A, Wiesner B, Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into cell interior non-endocytotically. Biochim Biophys Acta 1998;1414:127-39
   PubMed Web of Science ®Google Scholar
• Sanders ML, Donkor IO. A novel series of urea-based peptidomimetic calpain inhibitors. Bioorg Med Chem Lett 2006;16:1965-68
   PubMed Web of Science ®Google Scholar
• Donkor IO, Zheng Z, Miller DD. Synthesis and calpain inhibitory activity of alpha-ketoamides with 2,3-methanoleucine stereoisomers at the P2 position. Bioorg Med Chem Lett 2000;10:2497-500
   PubMed Web of Science ®Google Scholar
• Wolff ME. Burger's Medicinal Chemistry and Drug Discovery. Volume 1. John Wiley and Sons, Inc., Principles and Practice, New York; 1995
   Google Scholar
• Donkor IO, Korukonda R. Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position. Bioorg Med Chem Lett 2008;18:4806-8
   PubMed Web of Science ®Google Scholar
• Cuerrier D, Moldoveanu T, Inoue J, Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography. Biochem 2006;45:7446-52
   PubMed Web of Science ®Google Scholar
• Li Q, Hanzlik RP, Weaver RF, Molecular mode of action of a covalently inhibiting peptidomimetic on the human calpain protease core. Biochem 2006;45:701-8
   PubMed Web of Science ®Google Scholar
• Moldoveanu T, Campbell RL, Cuerrier D, Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J Mol Biol 2004;343:1313-26
   PubMed Web of Science ®Google Scholar
• Jones MA, Morton JD, Coxon JM, Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. Bioorg Med Chem 2008;16:6911-23
   PubMed Web of Science ®Google Scholar
• Abell AD, Jones MA, Neffe AT, Investigation into the P3 binding domain of m-calpain using photoswitchable diazo- and triazene-dipeptide aldehydes: new anticataract agents. J Med Chem 2007;50:2916-20
   PubMed Web of Science ®Google Scholar
• Abell AD, Brown KM, Coxon JM, Synthesis and evaluation of eight-membered cyclic pseudodipeptides. Peptides 2005;26:251-58
   PubMed Web of Science ®Google Scholar
• Abell AD, Jones MA, Coxon JM, Molecular modeling, synthesis, and biological evaluation of macrocyclic calpain inhibitors. Angew Chem Int Ed 2009;48:1455-58
   PubMed Web of Science ®Google Scholar
• Tyndall JDA, Nall T, Fairlie DP. Proteases universally recognize beta strands in their active sites. Chem Rev 2005;105:973-99
   PubMed Web of Science ®Google Scholar
• Inoue J, Nakamura M, Cui Y-S, Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinly (SJA6017) as a potent calpain inhibitor. J Med Chem 2003;46:868-71
   PubMed Web of Science ®Google Scholar
• Tamad Y, Fukiage C, Mizutani K, Calpain inhibitor, SJA6017, reduces the rate of formation of selenite cataract in rats. Curr Eye Res 2001;22:280-85
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Nakajima T, Fukiage C, Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. Curr Eye Res 2000;21:571-80
   PubMed Web of Science ®Google Scholar
• Kupina NC, Nath R, Bernath EE, The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma 2001;18:1229-40
   PubMed Web of Science ®Google Scholar
• Senju Pharmaceutical Co. Ltd. Alpha–Ketoamide derivatives and use there of. US7022738; 2006
   Google Scholar
• Payne RJ, Brown KM, Coxon JM, Peptidic aldehyde based on alpha– and beta–amino acids: Synthesis, inhibition of m-calpain and anti-cataract properties. Aust J Chem 2004;57:877-84
   Web of Science ®Google Scholar
• Donkor IO, Korukonda R, Huang TL, Peptidyl aldehyde inhibitors of calpain incorporating P2-proline mimetics. Bioorg Med Chem Lett 2003;13:783-4
   PubMed Web of Science ®Google Scholar
• Korukonda R, Guan N, Dalton JT, Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha–ketoamides. J Med Chem 2006;49:5282-90
   PubMed Web of Science ®Google Scholar
• Cuerrier D, Moldoveanu T, Campbell RL, Development of calpain-specific inactivators by screening of positional scanning epoxide libraries. J Biol Chem 2007;282:9600-11
   PubMed Web of Science ®Google Scholar
• Bihovsky R, Tao M, Mallamo JP, 1,2-Benzothiazine 1,1-dioxide alpha-ketoamide analogues as potent calpain I inhibitors. Bioorg Med Chem Lett 2004;14:1035-8
   PubMed Web of Science ®Google Scholar
• Donkor IO, Zheng X, Han J, Significance of hydrogen bonding at the S1′ subsite of calpain I. Bioorg Med Chem Lett 2001;11:1753-5
   PubMed Web of Science ®Google Scholar
• Josef KA, Kauer FW, Bihovsky R. Potent peptide alpha-ketohydroxamate inhibitors of recombinant human calpain I. Bioorg Med Chem Lett 2001;11:2615-17
   PubMed Web of Science ®Google Scholar
• Cephalon, Inc. Hydroxamate-Containing Cysteine and Serine Protease Inhibitors. WO0016767; 2001
   Google Scholar
• Donkor IO, Han J, and Zheng X. Design, synthesis, molecular modeling studies, and calpain inhibitory activity of novel alpha-ketoamides incorporating polar residues at the P1′-position. J Med Chem 2004;47:72-9
   PubMed Web of Science ®Google Scholar
• Donkor IO, Assefa H, Liu J. Structural basis for the potent calpain inhibitory activity of peptidyl alpha-ketoacids. J Med Chem 2008;51:4346-50
   PubMed Web of Science ®Google Scholar
• Tripathy R, Ator MA, Mallamo JP. Calpain inhibitors based on the quiescent affinity label concept: high rates of calpain inactivation with leaving groups derived from N-hydroxy peptide coupling reagents. Bioorg Med Chem Lett 2000;10:2315-19
   PubMed Web of Science ®Google Scholar
• Battaglia F, Trinchese F, Liu S, Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci 2003;20:357-62
   PubMed Web of Science ®Google Scholar
• Qian J, Cuerrier D, Davies PL, Cocrystal structures of primed side-extending alpha-ketoamide inhibitors reveal novel calpain-inhibitor aromatic interactions. J Med Chem 2008;51:5264-70
   PubMed Web of Science ®Google Scholar
• Ovat A, Li ZZ, Hampton CY, Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem 2010;53:6326-36
   PubMed Web of Science ®Google Scholar
• Cuerrier D, Moldoveanu T, Davies PL. Determination of peptide substrate specificity for calpain 1 by a peptide library-based approach. J Biol Chem 2005;280:40632-41
   PubMed Web of Science ®Google Scholar
• Nakamura M, Inoue J. Exploration of peptidyl hydrazones as water-soluble calpain inhibitors. Bioorg Med Chem Lett 2002;12:1603-6
   PubMed Web of Science ®Google Scholar
• Shirasaki Y, Nakamura M, Yamaguchi M, Exploration of orally available calpain inhibitors 2: Peptidyl hemiacetal derivatives. J Med Chem 2006;49:3926-32
   PubMed Web of Science ®Google Scholar
• Senju Pharmaceutical Co. Ltd. Cyclic hemiacetal derivatives and use thereof. US7202274; 2007
   Google Scholar
• Nakamura M, Yamaguchi M, Sakai O, Exploration of cornea permeable calpain inhibitors as anticataract agents. Bioorg Med Chem 2003;11:1371-79
   PubMed Web of Science ®Google Scholar
• Nakamura M, Miyashita H, Yamaguchi M, Novel 6-hydroxy-3-morpholinones as cornea permeable calpain inhibitors. Bioorg Med Chem 2003;11:5449-60
   PubMed Web of Science ®Google Scholar
• Shirasaki Y, Miyashita H, Yamaguchi M, Exploration of orally available calpain inhibitors: Peptidyl alpha-ketoamides containing an amphiphile at P3 site. Bioorg Med Chem 2005;13:4473-84
   PubMed Web of Science ®Google Scholar
• Shirasaki Y, Yamaguchi M, Miyashita H. Retinal penetration of calpain inhibitors in rats after oral administration. J Ocul Pharmacol Ther 2006;22:417-24
   PubMed Web of Science ®Google Scholar
• Oka T, Walkup RD, Tamada Y, Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl) amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. Neuroscience 2006;141:2139-45
   PubMed Web of Science ®Google Scholar
• Oka T, Nakajima T, Tamada Y, Contribution of calpains to photoreceptor cell death in N-methyl-N-nitrosourea-treated rats. Exp Neurol 2007;204:39-48
   PubMed Web of Science ®Google Scholar
• Ceptor Corp. Treatment of traumatic or degenerative neurologic, otologic or ophtalmologic diseases with targeted protease inhibitors. WO2005108353; 2006
   Google Scholar
• Weyermann P, Herzner H, Lescop C, Synthesis and evaluation of calpain inhibitors carrying muscle cell targeting groups. Lett Drug Design Dis 2006;3:152-8
   Web of Science ®Google Scholar
• Lescop C, Herzner, H, Siendt H, Novel cell-penetrating a-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. Bioorg Med Chem Lett 2005;15:5176-81
   PubMed Web of Science ®Google Scholar
• Santhera Pharmaceuticals. Alpha-ketocarbonyl calpain inhibitors. US20060258598; 2006
   Google Scholar
• Santhera Pharmaceuticals. Alpha-keto carbonyl calpain inhibitors. US20070293486; 2007
   Google Scholar
• Santhera Pharmaceuticals. Alpha-keto carbonyl calpain inhibitors. US20080058324; 2008
   Google Scholar
• Ceptor Corp. Compounds and kits for treating muscle disorders and methods of use thereof. WO2005124563; 2005
   Google Scholar
• Chabrier P.-E, Pignol B, Auvin S. PCT Int. Appl. WO0240016; 2002
   Google Scholar
• Auvin S, Pignol B, Navet E, Novel dual inhibitors of calpain and lipid peroxidation. Bioorg Med Chem Lett 2004;14:3825-8
   PubMed Web of Science ®Google Scholar
• Pignol B, Auvin S, Carre D, effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270. J Neurochem 2006;98:1217-28
   PubMed Web of Science ®Google Scholar
• Wang J, Pignol B, Chabrier P-E, A novel dual inhibitor of calpains and lipid peroxidation (BN82270) rescues the cochlea from sound trauma. Neuropharmacology 2007;52:1426-37
   PubMed Web of Science ®Google Scholar
• Fareed MU, Evenson AR, Wei W, Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 2006;290:R1589-97
   PubMed Web of Science ®Google Scholar
• Auvin S, Pignol B, Navet E, Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity. Bioorg Med Chem Lett 2006;16:1586-9
   PubMed Web of Science ®Google Scholar
• Lee KS, Seo SH, Lee YH, Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors. Bioorg Med Chem Lett 2005;15:2857-60
   PubMedGoogle Scholar
• Nam DH, Lee KS, Kim SH, Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors. Bioorg Med Chem Lett 2008;18:205-9
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jung SY, Jin C, Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. Bioorg Med Chem Lett 2009;19:502-7
   PubMed Web of Science ®Google Scholar
• Wells GJ, Tao M, Josef KA, 1,2-Benzothiazine 1,1-dioxide P2-P3 peptide mimetic aldehyde calpain I inhibitors. J Med Chem 2001;44:3488-503
   PubMed Web of Science ®Google Scholar
• Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors. US5952328; 1999
   Google Scholar
• Lubisch W, Hofmann HP, Treiber HJ, Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors. Bioorg Med Chem Lett 2000;10:2187
   PubMed Web of Science ®Google Scholar
• Abbott Labs. Derivatives from piperidine-keto acid, their preparation and use. US6380220; 2002
   Google Scholar
• Lubisch W, Moller A. Discovery of phenyl alanine derived ketoamides carrying benzoyl residues as novel calpain inhibitors. Bioorg Med Chem Lett 2002;12:1335-38
   PubMed Web of Science ®Google Scholar
• Lubisch W, Beckenbach E, Bopp S, Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem 2003;46:2404-12
   PubMed Web of Science ®Google Scholar
• Sinjoanu RC, Kleinschmidt S, Bitner RS, The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. Neurochem Int 2008;53:79-88
   PubMed Web of Science ®Google Scholar
• Neuhof C, Fabiunke V, Deibele K, Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts. Biol Chem 2004;385:1077-82
   PubMed Web of Science ®Google Scholar
• Basf Aktiengesellschaft. Benzamidoaldehydes and their use as cysteine protease inhibitors. US6251917; 2001
   Google Scholar
• Basf Aktiengesellschaft. Ketobenzamides as calpain inhibitors. US6103720; 2000
   Google Scholar
• Abbott Labs. Substituted amides, their production and their use. US6448254; 2002
   Google Scholar
• Abbott Labs. Heterocyclically substituted benzamides and their use. US6436949; 2002
   Google Scholar
• Basf Aktiengesellschaft. Heterocyclically substituted benxamides and their use in fighting diseases. US6172072; 2001
   Google Scholar
• Abbott Labs. Heterocyclically substituted amides, their production and their use. US6482832; 2002
   Google Scholar
• Abbott Labs. Heterocyclically substituted amides used as calpain inhibitors. US6562827; 2003
   Google Scholar
• Basf Aktiengesellschaft. Heterocyclically substituted amides, their preparation and use. US6630493; 2003
   Google Scholar
• Abbott GmbH & Co. Substituted amides, their preparation and use. US7276500; 2007
   Google Scholar
• Abbott Labs. Substituted benzamides, their production and their use as cysteine protease inhibitors. US6436925; 2002
   Google Scholar
• Abbott GmbH & Co. Carboxamide compounds and their use as calpain inhibitors. US 20100286146A1; 2010
   Google Scholar
• Abbott GmbH & Co. Carboxamide compounds and their use as calpain inhibitors. US7728012; 2010
   Google Scholar
• Montero A, Alonso M, Benito E, Studies on aromatic compounds: inhibition of calpain I by biphenyl derivatives and peptide-biphenyl hybrids. Bioorg Med Chem Lett 2004;14:2753-57
   PubMed Web of Science ®Google Scholar
• Montero A, Albericio F, Royo M, Solid-phase combinatorial synthesis of peptide-biphenyl hybrids as calpain inhibitors. Org Lett 2004;6:4089-92
   PubMed Web of Science ®Google Scholar
• Consejo Superior de Investigaciones Cientificas. Biphenyl derived thiamides as calpain inhibitors. US7476754; 2009
   Google Scholar
• Montero A, Mann E, Chana A, Peptide-biphenyl hybrids as calpain inhibitors Chem Biodivers 2004;1:442-57
   PubMed Web of Science ®Google Scholar
• Montero A, Albericio F, Royo M, Synthesis of a 24-membered cyclic peptide-biphenyl hybrid. Eur J Org Chem 2007:1301-8
   Web of Science ®Google Scholar
• Montero A, Mann E, Herradon B. The Overman rearrangement in carbohydrate chemistry: stereoselective synthesis of functionalized 3-amino-3,6-dihydro-2H-pyrans and incorporation in peptide derivatives. Tet Lett 2005;46:401-5
   Web of Science ®Google Scholar
• Man E, Chana A, Sanchez-Sancho F, Novel peptide-heterocycle hybrids: Synthesis and preliminary studies on calpain inhibition. Synth Catal 2002;344:855-67
   Web of Science ®Google Scholar
• Garcia BH, Martin RC, Redo VJA, Giner MA. Isoquinoline derivatives as calpain inhibitors. US20080090862; 2008
   Google Scholar
• Chicharro R, Alonso M, Aran VJ, Studies on calpain inhibitors. Synthesis of partially reduced isoquinoline-1-thione derivatives and conversion to functionalized 1-chloroisoquinolines. Tet Lett 2008;49:2275-9
   Web of Science ®Google Scholar
• Kang D-H, Jun K-Y, Lee JP, Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity. J Med Chem 2009;52:3093-9
   PubMed Web of Science ®Google Scholar
• Alvarez ME, Houck DR, White CB, Isolation and structure elucidation of two new calpain inhibitors from Streptomyces griseus. J Antibiot 1994;47:1195-201
   PubMed Web of Science ®Google Scholar
• Donkor IO, Sanders ML. Synthesis of a reported calpain inhibitor isolated from Streptomyces griseus. Bioorg Med Chem Lett 2001;11:2647-9
   PubMed Web of Science ®Google Scholar
• Zeng Y, Li Q, Hanzlik RP, Synthesis of a small library of diketopiperazines as potential inhibitors of calpain. Bioor Med Chem Lett 2005;15:3034-8
   PubMed Web of Science ®Google Scholar
• Kim HJ, Le JY, Kim S, A new epicatechin gallate and calpain inhibitory activity from Orostachys japonicus. Fitoterapia 2009;80:73-6
   PubMed Web of Science ®Google Scholar
• Silver K, Leloup L, Freeman LC, Non-steroidal anti-inflammatory drugs inhibit calpain activity and membrane localization of calpain 2 protease. Int J Biochem Cell Biol 2010;42:2030-6
   Google Scholar
• Jiang SX, Lertvorachon J, Hou ST, Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia. J Biol Chem 2005;280:33811-18
   PubMed Web of Science ®Google Scholar
• Wan W, DePetrillo PB. Ritonavir inhibition of calcium-activated neutral proteases. Biochem Pharm 2002;63:1481-4
   PubMed Web of Science ®Google Scholar
• Hadad N, Levy R, Schlaeffer F, Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition. Clin Vaccine Immunol 2007;14:1515-21
   PubMedGoogle Scholar
• DePetrillo PB, Wan W. Methods of and compounds for inhibiting calpains. US6448245; 2002
   Google Scholar
• Cuerrier D, Nie Z, Badley AD, Ritonavir does not inhibit calpain in vitro. Biochem Biophy Res Commun 2005;327:208-11
   PubMed Web of Science ®Google Scholar